Given that class I and class II HLA haplotypes play a crucial role in regulating T-cell immune activation and CTL-mediated tumor cell killing, their differences may play a significant role in determining the therapeutic efficacy and/or irAEs in patients receiving PD-1/PDL-1 blocking monoclonal antibody treatment (54). The gene discussed is PDCD1; the disease is neoplasm.